Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 11/04/26
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte OptionMarketBeat • 10/23/26
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a TurnaroundZacks Investment Research • 10/16/26
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast CancerGlobeNewsWire • 10/13/26
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/11/26
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective DegraderGlobeNewsWire • 09/10/26
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?Zacks Investment Research • 07/31/26
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/12/26
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a BetZacks Investment Research • 05/08/26
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten OfferingGlobeNewsWire • 04/20/26
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewsWire • 04/20/26
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical OfficerGlobeNewsWire • 04/15/26
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual MeetingGlobeNewsWire • 03/17/26
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026GlobeNewsWire • 03/10/26
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F InhibitorGlobeNewsWire • 02/03/26
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) ProgramsGlobeNewsWire • 12/06/25
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law FirmGlobeNewsWire • 11/26/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLDPRNewsWire • 11/20/25
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/12/25
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law FirmBusiness Wire • 11/12/25